Key Takeaways
- Big Idea Ventures has added five new startups to its Global Food Innovation Fund II (GFIF II) portfolio, spanning bioactive delivery, plant cell biomanufacturing, fermentation, cold chain stabilisation, and clean-label ingredient extraction.
- The cohort includes companies from Argentina, France, Mexico, and the United States, reflecting the fund's global mandate to back science-driven food system innovation.
- A common thread across the five companies is cost reduction and commercial scalability — advancing complex biotechnologies toward viable market entry by lowering capital intensity and de-risking R&D.
- The new portfolio companies gain access to Big Idea Ventures' global network of mentors, R&D resources, corporate partners, and investors through the GFIF II acceleration platform.
- GFIF II is backed by leading food corporations and remains focused on enhancing food security and sustainability at global scale.
Big Idea Ventures Adds Five Startups to Global Food Innovation Fund II
Big Idea Ventures has announced the addition of five new companies to its Global Food Innovation Fund II (GFIF II), bringing science-driven technologies across bioactive delivery, biomanufacturing, cold chain resilience, and ingredient extraction into its portfolio. The cohort reflects growing investor and industry demand for scalable solutions that improve efficiency and sustainability across the global food system.
“We invested in these five companies because they are developing science-driven technologies with the potential to strengthen the food system — from bioactive delivery and ingredient biomanufacturing to cold chain resilience, clean-label extraction, and scalable fermentation,” said Andrew D. Ive, Founder and Managing General Partner of Big Idea Ventures.
Meet the Big Idea Ventures GFIF II New Cohort
BioClé (Argentina/USA) has developed a bacterial extracellular vesicle (bEV) platform for targeted intracellular delivery of bioactives. By engineering high-yield bacterial strains, the company enables precise, scalable, and cost-competitive bioactive delivery for food, supplements, and nutrition manufacturers.
CryoVera (France) produces an anti-crystallisation molecule that prevents food texture degradation during cold chain logistics. Its stabilisers inhibit ice recrystallisation, preserving premium food quality and texture across global supply chains.
RheaPlant (USA) uses proprietary plant cell biomanufacturing technology to produce hard-to-source botanical ingredients with consistent, year-round output at significantly lower cost than conventional sourcing methods.
Saku Biosciences (USA) applies directed evolution to boost fermentation output, accelerate time to market for food and agriculture products, and enable more regionally distributed and resilient supply chains.
XiA'H (Mexico) transforms plant biomass into high-value bioactive ingredients using enzyme-based extraction, replacing solvents and heat. Backed by an extensive medicinal plant database, the company provides clean-label alternatives for food, agrifood, and industrial biotechnology applications.
Scaling Biotechnology to Commercial Viability
A shared focus across the cohort is the commercial accessibility of complex biotechnologies. Big Idea Ventures emphasises that the five companies are not only developing novel science but are advancing production approaches that reduce capital intensity, de-risk R&D processes, and accelerate the path to commercialisation — making innovation viable at the scale the food industry requires.
“From bioactive ingredients to technologies that enhance stability, bioavailability, and shelf life, these companies are enabling ‘less but better' food. By advancing more efficient, scalable production methods, they are making complex biotechnologies commercially viable,” said Caroline Mak, Senior Director of Acceleration at Big Idea Ventures.
1 Comment